BIOA

Business Context and Reporting Period

BioAge Labs, Inc. (BIOA) is a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging. The company is headquartered in Emeryville, California, and operates as a non-accelerated filer, smaller reporting company, and emerging growth company. This summary covers the quarterly period ended June 30, 2026 (Q2 2026).

Key Financial Metrics

Material Changes Versus Prior Period

• Revenue Growth: Collaboration revenue increased 35% year-over-year for the six months ended June 30, 2026, driven by increased employee effort under the Novartis collaboration agreement.
• Expense Increases: Total operating expenses rose 33% year-over-year for the six-month period. Research and development (R&D) expenses increased 45%, primarily due to the initiation of the Phase 2 QUELL-CV trial for BGE-102, start-up costs for the QUELL-DME trial, and increased personnel-related stock-based compensation.
• Debt Repayment: The company fully repaid its term loan (principal and final fee) in April 2026, resulting in negligible interest expense for the current period compared to the prior year.
• Capital Raising: In the first half of 2026, the company raised approximately $140 million through an underwritten public offering (including option exercise) and at-the-market (ATM) sales, significantly bolstering liquidity.

Guidance, Outlook, and Risks

Management Commentary and Outlook

Management estimates that existing cash, cash equivalents, and marketable securities ($381.3 million) are sufficient to fund operations and capital expenses through 2029. The company is advancing its lead candidate, BGE-102 (an NLRP3 inhibitor), with Phase 2 data readouts from the QUELL-CV trial expected in the second half of 2026. The company also plans to initiate the QUELL-DME trial in mid-2026 and intends to file the first Investigational New Drug (IND) application for its APJ agonist program by year-end 2026.

Risks and Contingencies

• Legal Proceedings: A putative securities class action regarding the company's IPO and azelaprag was dismissed with prejudice in March 2026. The plaintiff filed a notice of appeal, with oral arguments likely in early 2027.
• Supply Chain and Geopolitics: The company relies on third-party manufacturers in China and India. The BIOSECURE Act and the designation of WuXi AppTec (a key contractor) as a "biotechnology company of concern" on the 1260H List in June 2026 may restrict future government funding or require the company to seek alternative manufacturing relationships.
• Regulatory and Clinical Risks: As a clinical-stage company, BioAge faces significant risks regarding the success of clinical trials, regulatory approvals, and the potential for adverse safety signals, as previously experienced with the discontinuation of the azelaprag program.
• Financial Status: The company expects to continue incurring net operating losses for the foreseeable future and will require substantial additional capital to achieve profitability.

Investor Verification Checklist

• Verify the timeline and enrollment status of the QUELL-CV Phase 2 trial and the anticipated data readout in H2 2026.
• Assess the impact of the BIOSECURE Act and WuXi AppTec's designation on the company's manufacturing supply chain and potential need for alternative CDMOs.
• Monitor the status of the appealed securities class action lawsuit and potential settlement or defense costs.
• Review the burn rate and cash runway projections to confirm the ability to fund operations through 2029 without further dilution.
• Track the progress of the APJ agonist program and the expected IND filing timeline for late 2026.